相似文献
1
The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016.
JAMA. 2017 Dec 5;318(21):2137-2138. doi: 10.1001/jama.2017.14896.
2
US FDA's safety monitoring of drugs with expedited approval.
Lancet Oncol. 2016 Mar;17(3):281. doi: 10.1016/S1470-2045(16)00065-6. Epub 2016 Jan 29.
3
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
BMJ. 2015 Sep 23;351:h4633. doi: 10.1136/bmj.h4633.
4
Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.
Health Aff (Millwood). 2017 Aug 1;36(8):1408-1415. doi: 10.1377/hlthaff.2016.1541.
5
Expediting drug development--the FDA's new "breakthrough therapy" designation.
N Engl J Med. 2013 Nov 14;369(20):1877-80. doi: 10.1056/NEJMp1311439.
6
FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.
Food Drug Law J. 2016 Aug;71(1):135-157.
7
When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
FDA Consum. 1999 Sep-Oct;33(5):8-11, 13.
8
Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
Drug Discov Today. 2012 Aug;17(15-16):898-904. doi: 10.1016/j.drudis.2012.04.011. Epub 2012 May 5.
9
Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
Clin Pharmacol Ther. 2013 Aug;94(2):230-42. doi: 10.1038/clpt.2013.70. Epub 2013 Apr 3.
10
Medication development in opioid addiction: Meaningful clinical end points.
Sci Transl Med. 2018 Mar 28;10(434). doi: 10.1126/scitranslmed.aan2595.
引用本文的文献
1
Current landscape of US Food and Drug Administration use of expedited regulatory approvals for colorectal cancer care.
J Manag Care Spec Pharm. 2025 Sep;31(9):929-936. doi: 10.18553/jmcp.2025.31.9.929.
2
Comment on: "The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab".
Drugs. 2025 Feb;85(2):279-280. doi: 10.1007/s40265-024-02139-9. Epub 2024 Dec 20.
3
Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010-2019: a cross-sectional analysis.
BMJ Open. 2024 Mar 12;14(3):e076542. doi: 10.1136/bmjopen-2023-076542.
4
Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022.
Sci Rep. 2024 Feb 9;14(1):3325. doi: 10.1038/s41598-024-53554-7.
5
Comparison of the Latin America Regulation Landscape and International Reference Health Authorities to Hasten Drug Registration and Clinical Research Applications.
Ther Innov Regul Sci. 2023 Nov;57(6):1287-1297. doi: 10.1007/s43441-023-00565-7. Epub 2023 Sep 8.
6
Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics.
JAMA Netw Open. 2023 Aug 1;6(8):e2331753. doi: 10.1001/jamanetworkopen.2023.31753.
7
Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
Clin Transl Sci. 2023 Jul;16(7):1127-1133. doi: 10.1111/cts.13519. Epub 2023 Apr 4.
8
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
J Manag Care Spec Pharm. 2023 May;29(5):464-471. doi: 10.18553/jmcp.2023.22415. Epub 2023 Mar 29.
9
Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
JAMA Netw Open. 2022 Nov 1;5(11):e2239336. doi: 10.1001/jamanetworkopen.2022.39336.
10
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
JCO Oncol Pract. 2022 Sep;18(9):e1522-e1532. doi: 10.1200/OP.21.00909. Epub 2022 Jun 22.
本文引用的文献
1
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
JAMA. 2017 May 9;317(18):1854-1863. doi: 10.1001/jama.2017.5150.
2
Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation.
JAMA. 2016 Apr 12;315(14):1516-8. doi: 10.1001/jama.2015.16984.
3
A Randomized Trial Testing US Food and Drug Administration "Breakthrough" Language.
JAMA Intern Med. 2015 Nov;175(11):1856-8. doi: 10.1001/jamainternmed.2015.5355.
Zotero 插件